IN THE UNITED STATES PATENT AND TR

Applicant

: Håkan Larsson et al.

Serial No.

: TBA

Filing or 371(c) date: : June 8, 2006

For

: Use of Metabotropic Glutamarate Receptor 5

(MGluR5) Antagonists for the Treatment of

Gastrointestinal Disorders

Examiner

: TBA

Group Art Unit

: TBA

Docket No.

: 1103326-0909

Express Mail Label: EV 500402895 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, Box 1450, Alexandria,

VA 22313-1450, on **June 8, 2006**.

Signature of person mailing paper or fee

Mail Stop PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

The referenced application is the U.S. national stage application of international application no. PCT/SE2004/001819, filed December 7, 2004 (the "PCT application"). The documents identified on the attached Form PTO/SB/08A include documents cited in the

Page 2 of 2

10/582182

LAP20 Rec'd PCT/PTO 08 JUN 2006

specification and/or the International Search Report ("ISR") which issued in connection with the PCT application. Copies of the published PCT application, i.e., International Publication Number WO 2005/058321, and the ISR are being provided with this communication. The ISR is attached to and part of the published PCT application.

Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3) before the mailing date of the first Office Action on the merits and, therefore, no fee should be due. However, if any fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: Lico

Respectfully submitted,

John M. Genova Reg. No. 32,224

Customer No. 007470

Direct Dial: (212) 819-8437

IAP20 Rec'd PUTIFIO 08 JUN.

Complete if Known 82 TAQ 582 June 8, 2006

TBA

Håkan Larsson et al.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

First Named Inventor

Filing Date

Art Unit

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	(Ose as many sheets	43 110	Examiner Name IBA		
Sheet	1	of	1	Attorney Docket Number	1103326-0909

Examiner Initials	U.S. Cite Document Number No. Number-Kind Code ² (f known)		Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear					
		FOREIGN	N PATENT DO	CUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear					
		WO-00/20001	Apr. 13, 2000	Allgeier et al.						
		WO-01/72291	Oct. 4, 2001	Brotchie et al.						
		WO-02/078745	Oct. 10, 2002	Bear et al.		1				
		WO-03/074520	Sept. 12, 2003	Kyle et al.		T				
		WO-2004/058754	Jul. 15, 2004	Sun et al.						
	-					\vdash				
	ļ					}_				
	1 .	<u> </u>	<u> </u>			-				
Examiner Initials	Cite No.	NON PATENT Include name of the author (in CAPITAL LET serial, symposium, catalog, etc.), date, p	TERS), title of the arti			т				
		LIU et al., "Agonist- and Reflex-Evoked Internalization of Metabotropic Glutamate Receptor 5 in Enteric Neurons"; The Journal of Neuroscience, May 1, 2001, vol. 20, no. 9, pages 3200-3205.								
		MOAYYEDI et al., "Recent Developments in Gastroenterology"; BMJ, Dec. 14, 2002, vol. 325, pages 1399-1402.								
		OSSOWSKA et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-like Effects in Rats"; Neuropharmacology, 2001, vol. 41, page 413-420.								
-										

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 669. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.psto.gov or MPEP 901.04. 'Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emptor must precede the social number of the patent document. Kind of document by the appropriate symbols as indicated on the document meder WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is statched. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a bounding by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or such soft will be sent to the Chief Indomnstion Officer, U.S. Patent and Trademark Office. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.